Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis

(2014) Y. Okada   CLINICAL GENETICS

Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons

(2014) T Yoshimizu et al.   MOLECULAR PSYCHIATRY

What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit

(2014) C Barkus et al.   MOLECULAR PSYCHIATRY

Biological insights from 108 schizophrenia-associated genetic loci

(2014)   NATURE

Muscarinic acetylcholine receptors: novel opportunities for drug development

(2014) Andrew C. Kruse et al.   NATURE REVIEWS DRUG DISCOVERY

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

(2014) Daniel Umbricht et al.   JAMA Psychiatry

The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

(2013) Mathias Rask-Andersen et al.   Annual Review of Pharmacology and Toxicology

Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders

(2013) J. Bumb et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

(2013) Guangxu Jin et al.   DRUG DISCOVERY TODAY

Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia

(2013) Michael F. Egan et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia

(2013) Farzin Rezaei et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A rare mutation of CACNA1C in a patient with bipolar disorder and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain

(2013) E S Gershon et al.   MOLECULAR PSYCHIATRY

Genetics of rheumatoid arthritis contributes to biology and drug discovery

(2013) Yukinori Okada et al.   NATURE

DGIdb: mining the druggable genome

(2013) Malachi Griffith et al.   NATURE METHODS

Validating therapeutic targets through human genetics

(2013) Robert M. Plenge et al.   NATURE REVIEWS DRUG DISCOVERY

Bringing genome-wide association findings into clinical use

(2013) Teri A. Manolio   NATURE REVIEWS GENETICS

DrugBank 4.0: shedding new light on drug metabolism

(2013) Vivian Law et al.   NUCLEIC ACIDS RESEARCH

The NHGRI GWAS Catalog, a curated resource of SNP-trait associations

(2013) Danielle Welter et al.   NUCLEIC ACIDS RESEARCH

Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia

(2013) Sungwon Roh et al.   PSYCHOPHARMACOLOGY

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

(2013) Virginia L. Stauffer et al.   SCHIZOPHRENIA RESEARCH

Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia

(2012) Andrea de Bartolomeis et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

GENCODE: The reference human genome annotation for The ENCODE Project

(2012) J. Harrow et al.   GENOME RESEARCH

A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia

(2012) Mark Weiser et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

(2012) Susan L. McElroy et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Use of genome-wide association studies for drug repositioning

(2012) Philippe Sanseau et al.   NATURE BIOTECHNOLOGY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Next-Generation Treatments for Mental Disorders

(2012) T. R. Insel   Science Translational Medicine

Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

(2011) Surendra P. Singh et al.   CNS DRUGS

Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia

(2011) Amy F.T. Arnsten   INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Reengineering Translational Science: The Time Is Right

(2011) F. S. Collins   Science Translational Medicine

L-type calcium channels and psychiatric disorders: A brief review

(2010) Francesco Casamassima et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia

(2009) David de Lucena et al.   JOURNAL OF CLINICAL PSYCHIATRY

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure

(2008) Roger J. Hajjar et al.   JOURNAL OF CARDIAC FAILURE

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

(2008) Sekar Kathiresan et al.   NATURE GENETICS

A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia

(2008) Jeffrey A Lieberman et al.   NEUROPSYCHOPHARMACOLOGY